Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Azithromycin for cystic fibrosis.

K W Southern1, P M Barker

  • 1Institute of Child Health, University of Liverpool, Royal Liverpool Children's Hospital, Eaton Road, Alder Hey, Liverpool L12 2AP, UK. kwsouth@liv.ac.uk

The European Respiratory Journal
|November 2, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a multidisciplinary syllabus to support the education and training of roles in cystic fibrosis care: An ECFS Education initiative.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2025
Same author

ECFS standards of care on CFTR-related disorders: Identification and care of the disorders.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2024
Same author

ECFS standards of care on CFTR-related disorders: Towards a comprehensive program for affected individuals.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2024
Same author

Letter to the editor: Risk of false newborn screening after intra-uterine exposure to ETI.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
Same author

ECFS standards of care on CFTR-related disorders: Updated diagnostic criteria.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2022
Same author

Standards of care guidance for sweat testing; phase two of the ECFS quality improvement programme.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2022
Same journal

Beyond the 5th percentile: rethinking diagnostic thresholds in pulmonary function testing.

The European respiratory journal·2026
Same journal

A Transcriptomic Atlas of Chronic Lung Allograft Dysfunction.

The European respiratory journal·2026
Same journal

Risk of cancer and mortality in patients with interstitial lung diseases: Danish cohort study.

The European respiratory journal·2026
Same journal

Proposing a minimal important difference in NTproBNP in pulmonary arterial hypertension.

The European respiratory journal·2026
Same journal

Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis.

The European respiratory journal·2026
Same journal

Decoding the Lymphangioleiomyomatosis (LAM) Niche Microenvironment <i>via</i> Integrative Analysis of Single Cell Multiomics and Spatial Transcriptomics.

The European respiratory journal·2026
See all related articles

Azithromycin offers a small but significant improvement in respiratory function for cystic fibrosis (CF) patients. Close monitoring for side effects and antibiotic resistance is crucial.

Area of Science:

  • Pharmacology
  • Pulmonology
  • Infectious Diseases

Background:

  • Azithromycin is being investigated as a novel therapy for cystic fibrosis (CF) lung disease.
  • Beyond its antibacterial properties, azithromycin exhibits potential anti-inflammatory effects.
  • Unique pharmacokinetic properties of azithromycin may influence resistance patterns.

Purpose of the Study:

  • To review the current evidence on azithromycin's efficacy and safety in managing cystic fibrosis.
  • To discuss the optimal dosing and treatment duration for azithromycin in CF patients.
  • To highlight the importance of monitoring azithromycin resistance in CF clinical practice.

Main Methods:

  • Review of three randomized controlled trials (RCTs) evaluating azithromycin in CF.

Related Experiment Videos

  • Inclusion of a recent meta-analysis confirming trial findings.
  • Assessment of reported adverse events and respiratory function improvements.

    • Main Results:

    • Azithromycin demonstrated a small but statistically significant improvement in forced expiratory volume in one second (FEV1) compared to placebo.
    • Mild adverse events such as wheeze, diarrhea, and nausea were more frequent in one trial.
    • No established consensus exists regarding optimal azithromycin dosage or treatment duration for CF.

    Conclusions:

    • Azithromycin shows promise as an adjunctive therapy for CF lung disease, improving respiratory function.
    • Careful patient monitoring is essential due to potential adverse events and emerging resistance.
    • Collaboration between clinical teams and microbiology departments is recommended to track resistance patterns.